A type of blood and bone marrow cancer. Also known as AML.
A type of hormone therapy used to reduce male hormones causing prostate cancer growth. Otherwise known as chemical castration. Also known as ADT.
A treatment for prostate cancer that blocks the action of androgens in the body. Also known as ART or ARDT.
Prostate cancer that has spread beyond the prostate gland to other parts of the body.
The removal of a small piece of tissue, which is then examined under a microscope.
An organ that holds urine.
A general term for a large group of diseases in which abnormal cells grow and spread throughout the body.
Cancer that is no longer responding to medical or surgical treatment that lowers testosterone.
Cancer that can be controlled by keeping testosterone levels low.
How long a patient responds to a cancer treatment before a disease progresses.
Extreme tiredness.
A type of genetic test that looks for inherited mutations that are present in every cell of the body and have been present since birth.
Chemicals released by glands into the bloodstream to control how organs and tissues function.
Cancer that has spread from where it started to a distant part of the body (metastatic) but still responds to treatments in the body.
A group of disorders caused by blood cells that are poorly formed or don’t work properly. Also known as MDS.
A treatment that uses a single drug or type of treatment to treat a disease.
The percentage of patients in a clinical trial who experience a complete or partial response to a treatment within a specific time period.
Another name for poly (adenosine diphosphate-ribose) polymerase inhibitor. PARP inhibitors are a type of cancer drug that target the PARP protein to prevent repair of damaged DNA in cancer cells so the cancer cells die. Also known as PARPi.
A walnut-sized gland that surrounds the male urethra, located between the bladder and the penis.
A type of genetic test that looks for acquired mutations in a confined set of cells or tissue.
A type of cancer treatment that stops cancer cells from replicating.
A male sex hormone produced mostly by the testicles, although a small amount is made by the adrenal glands.
An abnormal growth of body tissue, which can be benign (not cancerous) or malignant (cancerous).
RUBRACA tablets are a prescription medicine used in adults for:
RUBRACA tablets may cause serious side effects including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with RUBRACA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with RUBRACA. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily. Symptoms of low blood cell counts are common during treatment with RUBRACA, but can be a sign of serious problems, including MDS or AML.
Before you take RUBRACA, tell your healthcare provider about all of your medical conditions, including if you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of RUBRACA. Do not donate sperm during use and for 3 months after the last dose of RUBRACA.
What other important information should I know about RUBRACA?
Your healthcare provider will do blood tests before and every month during treatment with RUBRACA to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with RUBRACA until your blood cell counts improve.
Avoid spending time in sunlight while on RUBRACA since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.
What are the side effects of RUBRACA?
The most common side effects of RUBRACA in people with prostate cancer include: Tiredness or weakness, nausea, decrease in hemoglobin (anemia), changes in liver function tests, decreased appetite, rash, constipation, low blood cell counts, vomiting, and diarrhea. These are not all the possible side effects of RUBRACA. Call your healthcare provider for medical advice about side effects.
What other medications might interact with RUBRACA?
RUBRACA can increase the amounts of other medications you may be taking, which can increase the risk of side effects. Tell your healthcare provider about all your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
